PHARMANIAGA : WORLD FIRST HALAL VACCINE AND INSULIN PLANTS CONSTRUCTION NEARING 90% COMPLETION

PRESS RELEASE

FOR IMMEDIATE RELEASE

PHARMANIAGA'S WORLD FIRST HALAL VACCINE AND

INSULIN PLANTS CONSTRUCTION NEARING 90%

COMPLETION

SHAH ALAM, 21 OCT 2022 - Pharmaniaga LifeScience Sdn Bhd (PLS), a wholly-owned subsidiary of Pharmaniaga Berhad (Pharmaniaga) is progressing steadily towards establishing the world's first Halal vaccine and insulin plants. The Halal biopharmaceutical plants, targeted to be commercialised in 2024 for vaccine and 2025 for insulin, presently construction progress stands at 90% and 70% completion, respectively.

Datuk Zulkarnain Md Eusope, Group Managing Director of Pharmaniaga said both plants will assist the country to be self-sufficient and reduce import dependency on critical vaccines and insulin. The production of vaccines locally will also help to provide drug security for the nation against any future threats of the pandemic.

"These Halal vaccine and insulin projects undertaken at our EU-certifiedhigh-technology plant are the world's first and nation's effort in line with the Group's strategic growth pillar that would spur the future growth of the Halal biopharmaceutical industry of the nation.

"I am happy to inform that our Halal vaccine and insulin facility projects are progressing as planned. The Halal vaccine plant is targeted to be ready in Quarter 3 of 2024, while the Halal insulin plant will be completed in Quarter 4 of 2025. The entire team has been working tirelessly and remains committed towards achieving this goal.

"The expansion into the Biopharmaceutical industry has been planned since 2017, even before the onset of the COVID-19 pandemic. Pharmaniaga will be partnering with reputable partners for technology transfers. As such, parallelly, registration is on going with the authorities for the product to be produced in the facility," said Datuk Zulkarnain.

In early October, PLS received shipments of equipment for the vaccine plant, which consist of Washer-Steriliser, Denester, Automatic Visual Inspection (AVI) and labelling machine after completing the Factory Acceptance Tests (FATs) in July this year. The other remaining FATs for Purified Water, Water for Injection and Pure Steam Generator, are planned and expected to be completed in December 2022.

Other FATs to be undertaken prior to the completion of the Halal insulin expansion project include; FATs for labelling and blister packing machine, planned for end 2022 and FATs for Washer-Steriliser, Cartridge filling machine, and Automatic Visual Inspection (AVI) machine, scheduled for 2023.

1

The Manufacturing Division of Pharmaniaga comprises six manufacturing plants across Malaysia and two in Indonesia which produce a range of products from pharmaceuticals, biopharmaceuticals, over-the-counter (OTC) to nutraceuticals. These include products catering to different therapeutic categories such as cardiovascular, respiratory, gastrointestinal, anti-diabetic, analgesics, anti-infectives, vaccines, insulins and health supplements for the local and international markets.

Pharmaniaga Berhad is the leading pharmaceutical Company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy. With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena. For more information, please log on to https://pharmaniaga.com/.

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Najmuddin Abdullah at 019-3387777, email, [e-mail] Dato' Zuhri Iskandar Kamarzaman at 03-3342 9999 ext 434 or email [e-mail].

2